Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) have earned an average recommendation of "Hold" from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have issued a buy recommendation on the

SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon™ technology for use in up to three drug targets.

SG Americas Securities LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 35.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 35,093 shares of the biopharmaceutical company's stock after purchasing an additional 9,260 shares during the quarter. SG Americas Securities

Element Squared LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 17,726 shares of the biopharmaceutical company's stock, valued at approximately $1,193,000. Several other large investors have

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in

Congress Asset Management Co. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 9.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,302,180 shares of the biopharmaceutical company's stock after selling 134,353 shares during the quarter. Congress Asset Management Co. owned

CWA Asset Management Group LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ: HALO) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,475 shares of the biopharmaceutical company's stock, valued at approximately $907,000. Several other large

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

The latest buzz acronym in the investment community, spurred in part by the artificial intelligence (AI) trade, is HALO, or “heavy assets, low obsolescence.” The catchy acronym is relevant to dividend investors because many of the companies in the hard assets realm are dividend payers.

Alliancebernstein L.P. reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 22.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,907,355 shares of the biopharmaceutical company's stock after selling 547,913 shares during the quarter. Alliancebernstein L.P. owned 1.62% of Halozyme